Figure 5
Anti-angiogenic effects of combination therapy with sorafenib and everolimus in PTEN-deficient prostate cancer. Assays of MVD assessed in prostate tumors from mice with CNPC and CRPC after drug interventions. (A) Representative images showing CD31 immunostaining of prostate tumors after the indicated treatment. Scale bars represent 100 μm. (B) Quantitative analysis of MVD according to the presence of CD31-positive microvessels. Values are expressed as the mean ± s.e., *P < 0.05.